The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Validation, 2011Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief
Objective/Rationale:
Endogenous activation of the Delta opioid receptor (DOR) serves as a compensatory mechanism to alleviate Parkinson’s disease (PD) symptoms. However, DOR-mediated convulsions have... -
Dyskinesia, 2011Targeting Dramatically Activated Astrocytic Networks for Managing LID: a Target Validation Program
Objective/Rationale:
Astrocytes have long been regarded as passive partners of neurons in the central nervous system but this view has been challenged. Although astrocytes are now known to actively... -
Research Grant, 2011Identifying Markers of PD Onset and Progression in a Prospective Cohort of Patients and ASymptoms & Side Effects Carriers of LRRK2 Mutations
Objective/Rationale:
LRRK2 mutations constitute one of the most common genetic risk factors for PD. The prospective follow-up of PD patients and aSymptoms & Side Effects carriers of LRRK2 mutations... -
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011Predicting Cognitive Profiles in Parkinson's Disease: A Multimodal Approach
Objective/Rationale:
Our proposal aims to determine the optimum combination of techniques to detect rate of cognitive decline in people with newly diagnosed Parkinson’s disease (PD). We will apply... -
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus... -
Resource: Utilizing DATATOP Biospecimens, 2011C-type Natriuretic Peptide (CNP): A Putative Biomarker of Neuronal Damage in Parkinson's Disease
Objective/Rationale:
CNP is a peptide produced by brain tissues where it acts to promote growth of nerve cells and their connections. Recent research in healthy humans has identified high...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.